Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Targeting brain protein may help treat MEF2C-related neurological disorders (opens in a new tab)

news-medical.net · 2026-11-04

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. One other point was not covered by the paper.

  • 2 supported
  • 2 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of five claims overstate the study. Two of five check out. One claim the study doesn't address.

  • 2 supported
  • 2 overstated
  • 1 not covered
Open claim evidence
3

The source study

Hyperfunction of PSD-95 leads to hyperexcitability and cognitive abnormalities in MEF2C haploinsufficiency

Proceedings of the National Academy of Sciences · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedIn mice with only one copy of MEF2C, the animals had profound seizures and cognitive impairments, and PSD-95 levels were elevated in their brains.View evidenceHide evidence

As statedprofound seizures

Why this verdict

The profile supports elevated PSD-95 in the MEF2C-haploinsufficient mouse model and reports increased seizure susceptibility; it also supports cognitive/behavioral deficits indirectly through rescue of cognitive behaviors after PSD-95 knockdown. But the story's wording that mice 'had profound seizures' goes beyond the abstract-level evidence, which reports increased susceptibility to seizures rather than profound or spontaneous seizures. The story also simplifies the model as mice with one copy of MEF2C, while the profile specifies MEF2C haploinsufficiency targeted to forebrain excitatory neurons.

1

Study evidence

MEF2C haploinsufficiency in forebrain excitatory neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.

“MEF2C haploinsufficiency in forebrain excitability neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.”
2

Study evidence

MEF2C haploinsufficiency in forebrain excitatory neurons increased seizure susceptibility in mice (reported in abstract).

“...increased susceptibility to seizures.”
Claim 2 of 5OverstatedReducing PSD-95 by knocking down one copy of the PSD-95 gene or by giving a drug that inhibits PSD-95 interaction with its receptor restored novel object recognition and social novelty recognition and returned severe seizures to the normal range in MEF2C-haploinsufficient mice.View evidenceHide evidence

As statedsevere seizures were restored back to the normal range

Why this verdict

The abstract-level profile supports a causal intervention claim in broad terms: reducing PSD-95 function by knockdown or disrupting PSD-95–NMDA receptor interaction reduced hyperexcitability/seizure-related phenotypes, and PSD-95 knockdown significantly improved cognitive behaviors. However, the story states more specific and stronger results than the abstract-level evidence provides: restoration of novel object recognition and social novelty recognition, knockdown of one copy of the PSD-95 gene, a drug intervention, and severe seizures returned to the normal range. The supplied profile supports reduction/improvement, not full restoration or normalization, and does not verify those specific behavioral assays or seizure-normalization details at abstract depth.

1

Study evidence

Reducing PSD-95 function (via PSD-95 knockdown or disrupting PSD-95–NMDA receptor interaction) reduced hyperexcitability and seizure-related phenotypes in MEF2C haploinsufficient mice.

“Knocking down PSD-95... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
2

Study evidence

Pharmacologic/peptidic inhibition of the PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.

“...or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
Claim 3 of 5Not coveredThe researchers said MEF2C deletions or mutations are associated with neurological and developmental disorders including autism, epilepsy and Alzheimer's disease, and that MEF2C haploinsufficiency is characterized by intellectual disability, autism spectrum disorder and seizures.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that MEF2C haploinsufficiency syndrome is characterized by intellectual disability, epilepsy, and autism-associated behaviors. However, the broader statement that MEF2C deletions or mutations are associated with a range of disorders including Alzheimer's disease is not present in the supplied abstract-level profile, so that part is not verifiable at this evidence depth.

1

Study evidence

MEF2C haploinsufficiency in forebrain excitatory neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.

“MEF2C haploinsufficiency in forebrain excitability neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.”
Claim 4 of 5SupportedA particular signaling protein in the brain could be a therapeutic target for neurological disorders arising from the deletion of the autism-linked gene MEF2C, according to a new mouse study.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the story's hedged, preclinical framing that PSD-95 could be a therapeutic target: PSD-95 knockdown or disruption of PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes, and PSD-95 knockdown improved cognitive behaviors in MEF2C-haploinsufficient mice. The headline is acceptable because it says 'could' and identifies this as a mouse study, though the evidence is limited to preclinical mouse data.

1

Study evidence

Reducing PSD-95 function (via PSD-95 knockdown or disrupting PSD-95–NMDA receptor interaction) reduced hyperexcitability and seizure-related phenotypes in MEF2C haploinsufficient mice.

“Knocking down PSD-95... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
2

Study evidence

Pharmacologic/peptidic inhibition of the PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.

“...or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
Claim 5 of 5SupportedThe researchers published the findings in Proceedings of the National Academy of Sciences.View evidenceHide evidence

Why this verdict

The supplied paper profile identifies the document with a PNAS DOI prefix/path, consistent with publication in Proceedings of the National Academy of Sciences. This is a profile-level bibliographic point rather than evidence from a specific appraisal unit.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The mouse model is MEF2C haploinsufficiency targeted to forebrain excitatory neurons.

    The story says mice had only one copy of MEF2C, but it does not reflect the model's forebrain excitatory neuron-specific targeting, which matters for generalizing the findings across brain regions, cell types, or human MEF2C-related disease.

    From Genetic mouse model of MEF2C haploinsufficiency targeted to forebrain excitatory neurons (in vivo); in vivo animal; in_v

  • The abstract does not provide quantitative effect sizes, sample sizes, statistical details, or full methodological details for seizure, excitability, knockdown, inhibitor, or behavioral assays.

    The story's caveats mention the mouse-study nature and planned further work, but they do not acknowledge that the abstract-level evidence lacks quantitative results, sample sizes, assay details, blinding/randomization information, and statistical metrics.

    From in vivo animal; in_vivo seizure susceptibility assay (unspecified); in_vivo_knockdown_intervention; in_vivo_pharmacologi

3 things the story did carry across
  • The study is preclinical in vivo mouse research, not human clinical evidence.
  • MEF2C haploinsufficiency was associated with elevated PSD-95, increased structural synapses, increased NMDA receptor surface expression, augmented neuronal excitability, and increased seizure susceptibility.
  • PSD-95-targeting interventions reduced hyperexcitability/seizure-related phenotypes and PSD-95 knockdown improved cognitive behaviors.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalReducing PSD-95 function (via PSD-95 knockdown or disrupting PSD-95–NMDA receptor interaction) rescues hyperexcitability/seizure-related phenotypes in MEF2C haploinsufficient mice.in vivo knockdown interventionExpand

In plain English

In MEF2C haploinsufficient mice, experimentally reducing PSD-95 function (by PSD-95 knockdown or by disrupting PSD-95–NMDA receptor interactions) reduced neuronal hyperexcitability and seizure-related phenotypes.

Key findings

  • Reducing PSD-95 function (via PSD-95 knockdown or disrupting PSD-95–NMDA receptor interaction) reduced hyperexcitability and seizure-related phenotypes in MEF2C haploinsufficient mice.
“Knocking down PSD-95... efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
What this piece can’t prove
  • Abstract does not specify the precise molecular approach used for PSD-95 knockdown, dose/extent of reduction, timing, or validation details.

3 further details could not be confirmed from the summary.

2in vivo animalMEF2C haploinsufficiency in forebrain excitatory neurons elevates PSD-95 and is associated with increased synapse number, altered NMDA receptor surface expression, neuronal hyperexcitability, and seizure susceptibility in mice (mechanistic link to MCHS phenotypes).Genetic mouse model of MEF2C haploinsufficiency targeted to forebrain excitatory neurons (in vivo)Expand

In plain English

In a mouse model with MEF2C haploinsufficiency targeted to forebrain excitatory neurons, the authors report elevated postsynaptic density protein 95 (PSD-95) that coincided with an increased number of structural synapses and increased surface expression of NMDA receptors, based on molecular and synaptic phenotyping in vivo.

Key findings

  • MEF2C haploinsufficiency in forebrain excitatory neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.
  • Elevation of PSD-95 coincided with an increased number of structural synapses in the same MEF2C-haploinsufficient mice.
“MEF2C haploinsufficiency in forebrain excitability neurons led to an elevation of postsynaptic density protein 95 (PSD-95) in mice.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

3in vivo animalMEF2C haploinsufficiency in forebrain excitatory neurons elevates PSD-95 and is associated with increased synapse number, altered NMDA receptor surface expression, neuronal hyperexcitability, and seizure susceptibility in mice (mechanistic link to MCHS phenotypes).Expand

In plain English

Abstract-level evidence from the paper reports that MEF2C haploinsufficiency in forebrain excitatory neurons is associated with augmented neuronal excitability in mice; PSD-95 elevation is implicated in this phenotype and knockdown or pharmacologic disruption of PSD-95–NMDA receptor interactions reduced hyperexcitability.

Key findings

  • MEF2C haploinsufficiency in forebrain excitatory neurons is associated with augmented neuronal excitability in mice.
  • Knockdown of PSD-95 or inhibition of the PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.
“...augmented neuronal excitability...”
What this piece can’t prove
  • Unclear whether reported excitability measures were performed in vivo or ex vivo, and whether they directly measured single-cell intrinsic excitability, synaptic-driven network activity, or field potentials.

2 further details could not be confirmed from the summary.

4in vivo animalMEF2C haploinsufficiency in forebrain excitatory neurons elevates PSD-95 and is associated with increased synapse number, altered NMDA receptor surface expression, neuronal hyperexcitability, and seizure susceptibility in mice (mechanistic link to MCHS phenotypes).in vivo seizure susceptibility assay (unspecified)Expand

In plain English

In mice with forebrain excitatory neuron–specific MEF2C haploinsufficiency, the study reports increased susceptibility to seizures compared with control mice; this seizure susceptibility co-occurred with elevated PSD-95, increased structural synapse number, enhanced NMDA receptor surface expression, and augmented neuronal excitability (abstract).

Key findings

  • MEF2C haploinsufficiency in forebrain excitatory neurons increased seizure susceptibility in mice (reported in abstract).
“...increased susceptibility to seizures.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5in vivo animalReducing PSD-95 function (via PSD-95 knockdown or disrupting PSD-95–NMDA receptor interaction) rescues hyperexcitability/seizure-related phenotypes in MEF2C haploinsufficient mice.in vivo pharmacologic inhibitionExpand

In plain English

The abstract reports that pharmacologic/peptidic inhibition of the PSD-95–NMDA receptor interaction in MEF2C haploinsufficient mice efficiently reduced hyperexcitability phenotypes (including increased seizure susceptibility described for the model).

Key findings

  • Pharmacologic/peptidic inhibition of the PSD-95–NMDA receptor interaction reduced hyperexcitability phenotypes in MEF2C haploinsufficient mice.
“...or inhibiting the interaction between PSD-95 and NMDA receptors efficiently reduced hyperexcitability phenotypes in MEF2C haploinsufficiency.”
What this piece can’t prove
  • Abstract does not provide quantitative effect sizes, sample sizes, or statistical details for the reported reduction in hyperexcitability.

2 further details could not be confirmed from the summary.

6in vivo animalPSD-95 knockdown improves cognitive behaviors in MEF2C haploinsufficient mice, supporting PSD-95 as a therapeutic target.in vivo animalExpand

In plain English

In MEF2C haploinsufficient mice, knockdown of PSD-95 produced a significant improvement in cognitive/behavioral performance compared with controls, leading authors to propose PSD-95 as a therapeutic target for cognitive deficits associated with MEF2C haploinsufficiency.

Key findings

  • Knocking down PSD-95 significantly improved cognitive behaviors in mice with MEF2C haploinsufficiency.
“Most importantly, knocking down PSD-95 significantly improved cognitive behaviors in mice with MEF2C haploinsufficiency.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Hyperfunction of PSD-95 leads to hyperexcitability and cognitive abnormalities in MEF2C haploinsufficiency

Proceedings of the National Academy of Sciences · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref · 41 candidate papers

Selected

Hyperfunction of PSD-95 leads to hyperexcitability and cognitive abnormalities in MEF2C haploinsufficiency

Proceedings of the National Academy of Sciences · 2026 · Crossref

Source (opens in a new tab)
Candidate

Functional traits explain the enhancement of denitrification by wetland plants

Journal of Plant Ecology · 2026 · Crossref

Source (opens in a new tab)
Candidate

Greenhouse gas emissions and control measures for constructed wetland: A systematic review

Journal of Environmental Management · 2026 · Crossref

Source (opens in a new tab)
Candidate

Capacity building initiatives in orthopaedic outreach: A barrier-strategy mapping tool

Journal of Orthopaedic Reports · 2026 · Crossref

Source (opens in a new tab)
Candidate

Wear Degradation of High-Nitrogen Austenitic Steels for Internal Combustion Engines in Hydrogen-Containing Alternative Fuels

Energies · 2026 · Crossref

Source (opens in a new tab)

And 35 more candidates considered.